AI Tokens
Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Adjustments to Financial Statements

Microsoft Excel

Adjustments to Total Assets

Cytokinetics Inc., adjusted total assets

US$ in thousands

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Total assets 1,014,775 841,319 533,803 289,814 211,178
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1 — — — — 10,355
Less: Noncurrent deferred tax assets, net2 — — — — —
After Adjustment
Adjusted total assets 1,014,775 841,319 533,803 289,814 221,533

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Noncurrent deferred tax assets, net. See details »


A significant and consistent upward trajectory in the asset base is observed between December 31, 2018, and December 31, 2022. Total assets grew from 211,178 thousand US dollars to 1,014,775 thousand US dollars, representing a substantial expansion of the balance sheet over the five-year period.

Asset Growth Pattern
The most rapid period of expansion occurred between 2019 and 2021, during which the asset base nearly tripled. Specifically, total assets increased from 289,814 thousand US dollars in 2019 to 841,319 thousand US dollars by the end of 2021, followed by a further increase to exceed 1 billion US dollars by the end of 2022.
Analysis of Asset Adjustments
A variance between total assets and adjusted total assets is present only for the period ending December 31, 2018. During this period, adjusted total assets were 221,533 thousand US dollars, reflecting a positive adjustment of 10,355 thousand US dollars over the reported total assets of 211,178 thousand US dollars.
Consistency of Reported Values
From December 31, 2019, through December 31, 2022, total assets and adjusted total assets are perfectly aligned. This indicates that no adjustments were applied to the total asset figures for four consecutive years, signifying a period of stability in how these assets were accounted for relative to the adjusted metric.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Total Liabilities

Cytokinetics Inc., adjusted total liabilities

US$ in thousands

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Total liabilities 1,122,675 597,456 420,420 300,751 185,244
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — — 10,355
Less: Noncurrent deferred tax liabilities2 — — — — —
Less: Deferred revenue — 87,000 87,000 — —
After Adjustment
Adjusted total liabilities 1,122,675 510,456 333,420 300,751 195,599

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Noncurrent deferred tax liabilities. See details »


A consistent and accelerating upward trend is observed in both total and adjusted total liabilities between 2018 and 2022. Total liabilities grew from 185,244 thousand US dollars in 2018 to 1,122,675 thousand US dollars by 2022, representing a substantial expansion of the company's financial obligations. The most significant increase occurred between 2021 and 2022, where the total liability figure nearly doubled.

Growth Trajectory
Total liabilities exhibited steady annual growth from 2018 through 2021, followed by an exponential surge in 2022. This pattern indicates a significant escalation in debt or accrued obligations toward the end of the analyzed period.
Liability Adjustments
Discrepancies between total liabilities and adjusted total liabilities are evident in several periods. In 2018, adjusted liabilities were higher than the reported total. In contrast, a significant downward adjustment of 87,000 thousand US dollars was applied in both 2020 and 2021, reducing the adjusted total liabilities relative to the reported total.
Convergence Analysis
Full convergence between total and adjusted liabilities occurred in 2019 and 2022. The total alignment in 2022 is particularly notable as it coincides with the peak liability value of 1,122,675 thousand US dollars, suggesting that no specific adjustments were required or applied during the year of the highest reported debt.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Stockholders’ Equity

Cytokinetics Inc., adjusted stockholders’ equity (deficit)

US$ in thousands

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Stockholders’ equity (deficit) (107,900) 243,863 113,383 (10,937) 25,934
Adjustments
Less: Net deferred tax assets (liabilities)1 — — — — —
Add: Deferred revenue — 87,000 87,000 — —
After Adjustment
Adjusted stockholders’ equity (deficit) (107,900) 330,863 200,383 (10,937) 25,934

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Net deferred tax assets (liabilities). See details »


The financial position of stockholders' equity exhibits significant volatility between 2018 and 2022, characterized by abrupt transitions between positive equity and equity deficits.

Equity Volatility and Trend Analysis
A cyclical pattern is observed where the equity position shifted from a surplus of $25.9 million in 2018 to a deficit of $10.9 million in 2019. This was followed by a period of substantial growth, peaking in 2021 with reported stockholders' equity of $243.9 million. However, this upward trajectory reversed sharply by December 31, 2022, resulting in a significant deficit of $107.9 million.
Analysis of Equity Adjustments
Adjusted stockholders' equity aligned perfectly with reported equity in 2018, 2019, and 2022. A notable divergence occurred during the 2020 and 2021 fiscal years. In 2020, adjusted equity was $87 million higher than reported equity, and in 2021, this variance increased to $87 million as well, with adjusted equity reaching $330.9 million. This suggests the application of specific accounting adjustments or reclassifications during those two years that temporarily bolstered the equity position.
Final Period Position
The transition from 2021 to 2022 represents the most significant contraction in the analyzed period. The shift from a reported positive equity of $243.9 million to a deficit of $107.9 million indicates a substantial erosion of capital or a significant increase in liabilities exceeding assets by the end of 2022.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Capitalization Table

Cytokinetics Inc., adjusted capitalization table

US$ in thousands

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Current portion of term loan — — — — 2,607
Short-term finance lease liabilities 1,000 500 — — —
Term loan, net, excluding current portion 63,810 47,367 46,209 45,052 39,806
Convertible notes, net 545,808 95,471 89,504 84,205 —
Long-term finance lease liabilities 1,001 805 — — —
Total reported debt 611,619 144,143 135,713 129,257 42,413
Stockholders’ equity (deficit) (107,900) 243,863 113,383 (10,937) 25,934
Total reported capital 503,719 388,006 249,096 118,320 68,347
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — — 10,355
Add: Short-term operating lease liabilities2 12,829 14,863 2,785 4,616 —
Add: Long-term operating lease liabilities3 126,895 112,229 440 2,195 —
Adjusted total debt 751,343 271,235 138,938 136,068 52,768
Adjustments to Equity
Less: Net deferred tax assets (liabilities)4 — — — — —
Add: Deferred revenue — 87,000 87,000 — —
Adjusted stockholders’ equity (deficit) (107,900) 330,863 200,383 (10,937) 25,934
After Adjustment
Adjusted total capital 643,443 602,098 339,321 125,131 78,702

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Short-term operating lease liabilities. See details »

3 Long-term operating lease liabilities. See details »

4 Net deferred tax assets (liabilities). See details »


The financial structure exhibits a period of significant capitalization expansion and increasing leverage from 2018 to 2022. A primary trend is the aggressive growth of total capital, which was accompanied by a sharp escalation in liabilities and high volatility in stockholders' equity.

Debt Obligations and Leverage
Total reported debt experienced a substantial increase, rising from 42.4 million US dollars in 2018 to 611.6 million US dollars by 2022. The most significant surge occurred between 2021 and 2022, where reported debt grew by approximately 323%. Adjusted total debt followed a similar trajectory but remained consistently higher than reported figures, reaching 751.3 million US dollars in 2022, indicating a substantial amount of capitalized liabilities beyond reported debt.
Equity Volatility
Stockholders' equity demonstrated significant instability over the five-year period. After starting at 25.9 million US dollars in 2018, the balance shifted to a deficit in 2019 before recovering to a peak of 243.9 million US dollars in 2021. This positive trend reversed sharply in 2022, resulting in a deficit of 107.9 million US dollars. The adjusted equity figures mirror this volatility, though they show significantly higher values in 2020 and 2021 compared to reported equity.
Analysis of Capitalization Adjustments
A consistent divergence is observed between reported and adjusted financial figures. In 2021, adjusted stockholders' equity was 87 million US dollars higher than reported equity, while adjusted total debt was 127.1 million US dollars higher than reported. By 2022, the disparity in debt obligations widened to 139.7 million US dollars, suggesting that adjustments to the capitalization table are increasingly driven by debt-like obligations not captured in the primary reported debt figure.
Total Capital Expansion
Adjusted total capital grew from 78.7 million US dollars in 2018 to 643.4 million US dollars in 2022. The most rapid expansion occurred between 2020 and 2021, where adjusted total capital increased from 339.3 million US dollars to 602.1 million US dollars. By 2022, the growth in total capital was sustained primarily by the massive increase in adjusted debt, which offset the decline into a stockholders' equity deficit.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Revenues

Cytokinetics Inc., adjusted revenues

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Revenues 94,588 70,428 55,828 26,868 31,501
Adjustment
Add: Increase (decrease) in deferred revenue (87,000) — 87,000 — —
After Adjustment
Adjusted revenues 7,588 70,428 142,828 26,868 31,501

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The reported revenue trajectory from 2018 through 2022 demonstrates an overall growth pattern, despite a minor contraction observed in 2019. Following that decline, revenues increased consistently year-over-year, growing from 26,868 thousand USD in 2019 to 94,588 thousand USD by the end of 2022.

Consistency of Adjusted Revenues
For the fiscal years 2018, 2019, and 2021, reported revenues and adjusted revenues are identical. This indicates that no adjustments were applied to the revenue figures during these specific periods.
Positive Revenue Adjustment
A substantial upward adjustment is observed in 2020. While reported revenues were 55,828 thousand USD, adjusted revenues were recorded at 142,828 thousand USD, representing a significant positive variance.
Negative Revenue Adjustment
A sharp downward adjustment occurred in 2022. Despite reported revenues reaching a five-year peak of 94,588 thousand USD, the adjusted revenues plummeted to 7,588 thousand USD, indicating a major exclusion or correction in the adjusted reporting.
Comparative Trend Analysis
The divergence between reported and adjusted revenues is inconsistent. The growth trend seen in reported revenues is not mirrored in the adjusted figures, which exhibit extreme volatility specifically in 2020 and 2022.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Reported Income

Cytokinetics Inc., adjusted net loss

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Net loss (388,955) (215,314) (127,290) (121,692) (106,289)
Adjustments
Add: Deferred income tax expense (benefit)1 — — — — —
Add: Increase (decrease) in deferred revenue (87,000) — 87,000 — —
Add: Other comprehensive income (loss) (2,721) (1,018) (530) 179 157
After Adjustment
Adjusted net loss (478,676) (216,332) (40,820) (121,513) (106,132)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Deferred income tax expense (benefit). See details »


An analysis of the financial performance from 2018 to 2022 reveals a sustained increase in both reported net loss and adjusted net loss, characterized by an accelerating downward trend in the latter years of the period.

Net Loss Trajectory
Reported net losses grew steadily from -106,289 thousand USD in 2018 to -127,290 thousand USD in 2020. A significant escalation occurred in 2021, where the loss increased to -215,314 thousand USD, followed by a sharp increase to -388,955 thousand USD by December 31, 2022, representing a substantial widening of the deficit over the five-year span.
Adjusted Net Loss Volatility
The adjusted net loss closely mirrored the reported net loss during 2018 and 2019. However, a significant divergence occurred in 2020, where the adjusted net loss was -40,820 thousand USD, a figure considerably lower than the reported loss of -127,290 thousand USD. This trend shifted by 2022, when the adjusted net loss reached -478,676 thousand USD, exceeding the reported net loss by approximately 89,721 thousand USD.
Analysis of Adjustments
The variance between reported and adjusted figures indicates the impact of non-recurring items or non-cash adjustments. The significant reduction in adjusted loss during 2020 suggests the exclusion of substantial expenses from the adjusted metric. In contrast, the 2022 figures suggest that the reported net loss was mitigated by specific gains or credits that were excluded from the adjusted net loss calculation, thereby resulting in a more severe adjusted deficit than the reported one.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?